Combined Treatment for Primary Central Nervous System Lymphoma
Author Information
Author(s): Stefan Hohaus, Luciana Teofili, Mario Balducci, Stefania Manfrida, Angelo Pompucci, Francesco D’Alo’, Giuseppina Massini, Luigi Maria Larocca, Roberto Marra, Sergio Storti
Primary Institution: Università Cattolica del Sacro Cuore
Hypothesis
Does the addition of high-dose cytosine arabinoside (HD-AraC) to high-dose methotrexate (HD-MTX) improve treatment outcomes for primary central nervous system lymphoma (PCNSL)?
Conclusion
The addition of HD-AraC did not improve clinical outcomes in PCNSL and increased treatment-related toxicity.
Supporting Evidence
- 67% of assessable patients achieved complete remission after treatment.
- Severe infections occurred in 77% of patients receiving HD-AraC.
- Median overall survival was 22 months.
Takeaway
Doctors tried adding a new medicine to help patients with brain lymphoma, but it didn't make them better and made them sicker instead.
Methodology
Patients received high-dose methotrexate followed by whole brain radiotherapy, with some receiving additional high-dose cytosine arabinoside.
Potential Biases
Potential bias due to non-randomized treatment allocation.
Limitations
The study is limited by its small sample size and retrospective nature.
Participant Demographics
41 HIV-negative patients, median age 59 years, 21 females and 20 males.
Statistical Information
P-Value
0.5
Confidence Interval
95% C.I., 11–39
Statistical Significance
p=0.5
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website